clinical trial · NCT05106127
Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem
Evergreen Therapeutics, Inc.·phase2·not yet recruiting·n = 28
Advanced Endometrial CancerEG-007Pembrolizumab 100 mg/4 mL (25 mg/ml) InjectionLenvatinib Capsules
brief summary
This is a Phase 2 trial Safety Lead-in trial conducted in 3 cohorts of patients. A safety lead-in study of the impact of adding the Repurposed Drugs a third agent will be conducted prior to opening enrollment into the compassionate use study. All patients enrolled in the safety lead-in study may continue long-term treatment under this protocol without interruption of dosing.
started
Aug 1, 2026
primary completion
Mar 1, 2027
completion
Mar 1, 2027
last updated
Dec 8, 2025
official title
A Phase 2, Open-Label, Safety Lead-In With Long Term Safety Study of EG-007, Added to the Combination of Lenvatinib Plus Pembrolizumab
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol